Antibiotic-Eluting Hemostatic Matrix for Sustained Wound-Site Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing surgical site infections (SSIs) are inadequate, particularly in orthopedic surgeries, as they often rely on systemic antibiotic administration, which can lead to antibiotic resistance and do not provide sustained antimicrobial presence at the surgical site.
Innovation Solution
Development of biodegradable hemostatic agents that combine antibiotics with gelatin or chitosan through peptide bond formation, allowing for both immediate and sustained release of active agents, such as antibiotics and NSAIDs, via crosslinked matrices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic antibiotic administration is used to prevent surgical site infections, then antimicrobial coverage is achieved, but antibiotic resistance increases and sustained antimicrobial presence at the surgical site is not maintained
Solution Approach 1:
The patent extracts the antimicrobial function from systemic administration and places it directly at the surgical site through hemostatic agents. The hemostatic agents are applied topically to the surgical wound, releasing antibiotics locally to prevent infection without requiring systemic circulation, thereby eliminating the harmful effect of antibiotic resistance while maintaining effectiveness.
Solution Approach 2:
The hemostatic agent serves as an intermediary carrier that delivers antibiotics directly to the surgical site. The agent combines hemostatic functionality with controlled antibiotic release, acting as a localized reservoir that maintains therapeutic concentrations at the wound bed without systemic distribution, thus preventing resistance development.
2Reliability
If systemic antibiotic administration is used, then broad antimicrobial coverage is achieved, but sustained antimicrobial presence at the surgical site is not maintained
Solution Approach 1:
The hemostatic agent is applied preliminarily at the surgical site before infection can establish. The agent is impregnated with antibiotics and applied topically to the wound bed, creating an immediate localized antimicrobial environment that prevents bacterial colonization from the outset.
Solution Approach 2:
The hemostatic agent provides continuous antibiotic release over an extended period (up to 28 days) directly at the surgical site. The controlled release mechanism maintains therapeutic antibiotic concentrations continuously, ensuring sustained antimicrobial presence without the peaks and troughs associated with systemic administration.
3Reliability
If multiple antibiotics are administered systemically to prevent resistant infections, then antimicrobial coverage is improved, but treatment complexity and side effects increase
Solution Approach 1:
The hemostatic agent performs multiple functions simultaneously: it provides hemostasis (blood clotting) and serves as a controlled-release reservoir for antibiotics. This multi-functionality eliminates the need for separate systemic antibiotic regimens, simplifying the overall treatment approach while maintaining effective infection prevention.
Solution Approach 2:
The treatment concentrates antimicrobial action locally at the surgical site rather than distributing antibiotics systemically. The hemostatic agent is applied directly to the wound, creating a high-concentration antimicrobial environment precisely where needed, while avoiding unnecessary exposure of the rest of the body to multiple antibiotics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The agents provide controlled release of antibiotics and NSAIDs, reducing the risk of SSIs by maintaining effective antimicrobial levels at the surgical site for up to three weeks and minimizing systemic antibiotic use, thereby reducing resistance and improving surgical outcomes.
Implementation Method 1
combine antibiotics with gelatin or chitosan through peptide bond formation
Implementation Method 2
biodegradable hemostatic agents
Implementation Method 3
controlled drug release through a degradation or diffusion-controlled mechanism
Data Source
AI summary
A novel active agent-eluting hemostatic agent and methods of use and manufacture thereof are presented. A polymer, such as gelatin or chitosan, is used as the base for a hemostatic agent. The polymer is crosslinked with a chemical crosslinker, such as a carbodiimide, in the presence of an active agent. The active agent may be an anesthetic, chemotherapeutic agent, or antimicrobial, such as an antibiotic. The novel process allows for the active agent to be both covalently bound to the polymer as well as be trapped within cages in the polymer that are formed from the crosslinking. This dual measure allows for controlled and sustained release of the active agent from the hemostatic agent to deliver the active agents to the wound sites.